JM3A5 cells are sensitive to a variety of chemotherapeutic agents. (A) Fas-resistant JM3A5 cells (□) or wild-type Jurkat cells (▪) were incubated with 7C11 anti-Fas (100 ng/mL, 3 hours), etoposide (34 μmol/L, 6 hours), doxorubicin (0.5 μmol/L, 24 hours), topotecan (0.1 μmol/L, 24 hours), cisplatin (1 μmol/L, 48 hours), methotrexate (100 nmol/L, 24 hours), staurosporine (1 μmol/L, 6 hours), or γ-irradiation (1,200 cGy, followed by a 24-hour incubation) at 37°C. After treatment, cells were stained with propidium iodide and analyzed by flow cytometry. The percentage of hypodiploid cells is graphed. (B and C) JM3A5 cells (○) and wild-type Jurkat cells (•) were treated with 0 to 68 μmol/L (0 to 40 μg/mL) etoposide for 6 hours (B) or 0 to 500 nmol/L (0 to 300 ng/mL) doxorubicin for 24 hours (C) at 37°C before propidium iodide staining and flow cytometry as described above.